Atara Biotherapeutics (ATRA) vs Anavex Life Sciences (AVXL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 53.7% versus a loss of 81.9%. Over five years, AVXL leads with a -97.0% price change compared with -98.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $54.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | AVXL |
|---|---|---|
| Share price | $6.33 | $0.5915 |
| Market cap | $64.49M | $54.83M |
| 1-day change | -0.16% | -11.39% |
| YTD return | -65.01% | -83.38% |
| 1-year return | -53.73% | -81.86% |
| 5-year return | -98.56% | -96.96% |
| Forward P/E | 3.96 | — |
| EPS (TTM) | $-1.12 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | — |
| Revenue growth (YoY) | -6.33% | — |
| Net income (latest FY) | $32.69M | $-46.38M |
| Operating margin | 29.69% | — |
| Net margin | 27.07% | — |
| 52-week high | $19.15 | $5.36 |
| 52-week low | $3.92 | $0.59 |
| Distance from 52-week high | -66.94% | -88.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +115.96% | — |
| Average volume | 35.46K | 1.15M |
| Shares outstanding | 10.19M | 92.70M |
| Employees | 10 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed AVXL by 28.1 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
ATRA vs AVXL FAQ
Which is bigger, Atara Biotherapeutics or Anavex Life Sciences?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $54.83M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, ATRA or AVXL?
ATRA returned -53.73% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Anavex Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.